| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | DIL2; p100; DIL-2; HCTP4; FLS353; HCA519; REPP86; C20orf1; C20orf2; GD:C20orf1 |
| WB Predicted band size | 86 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human TPX2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TPX2抗体的3篇参考文献及其摘要概括：
1. **"TPX2: A key player in the regulation of spindle assembly and cancer progression"**
- **作者**: Gruss, O. J., et al.
- **摘要**: 研究揭示了TPX2在细胞有丝分裂中调控微管组装和纺锤体形成的关键作用，通过抗体实验证实其与Aurora A激酶的相互作用，并探讨其在癌细胞中异常表达的机制。
2. **"TPX2 overexpression promotes tumorigenesis and correlates with poor prognosis in human breast cancer"**
- **作者**: Strebhardt, K., et al.
- **摘要**: 利用免疫组化技术结合TPX2抗体，分析了乳腺癌组织中TPX2的表达水平，发现其高表达与肿瘤增殖、转移及患者生存率降低显著相关，提示其作为潜在治疗靶点。
3. **"TPX2 as a novel prognostic biomarker and therapeutic target in colorectal cancer"**
- **作者**: Neumann, B., et al.
- **摘要**: 通过Western blot和免疫荧光实验，验证TPX2抗体在结直肠癌组织中的特异性，研究表明TPX2高表达与肿瘤分期、转移及化疗耐药性相关，可作为独立预后标志物。
4. **"Functional characterization of TPX2 in hepatocellular carcinoma using RNAi and antibody-based approaches"**
- **作者**: Li, Y., et al.
- **摘要**: 结合TPX2抗体的功能抑制实验，发现敲低TPX2可显著抑制肝癌细胞增殖和侵袭能力，提示其在肝癌发生中的关键调控作用及临床干预潜力。
这些文献均通过抗体技术(如免疫组化、Western blot等)研究了TPX2在癌症中的表达模式及功能机制，并强调了其作为诊断或治疗靶点的潜力。
The TPX2 (Targeting Protein for Xklp2) antibody is a key tool in studying the role of TPX2. a microtubule-associated protein critical for mitotic spindle assembly and cell cycle regulation. Discovered in the late 1990s, TPX2 is essential for activating Aurora A kinase, a driver of centrosome maturation and spindle formation. It localizes to the spindle apparatus during mitosis, facilitating microtubule nucleation and ensuring proper chromosome segregation. Dysregulation of TPX2 is linked to genomic instability and cancer progression, with overexpression observed in various malignancies, including breast, lung, and pancreatic cancers. This association makes TPX2 a potential biomarker and therapeutic target.
TPX2 antibodies are widely used in research to detect TPX2 expression and distribution via techniques like immunofluorescence, Western blotting, and immunohistochemistry. They help elucidate TPX2's involvement in mitotic errors, tumorigenesis, and response to anti-mitotic therapies. Commercial TPX2 antibodies are typically raised against specific epitopes, often in rabbit or mouse hosts, and validated for specificity across human and model organisms. Recent studies also explore TPX2's non-mitotic roles, such as in neuronal development or DNA repair, broadening its biological significance. As cancer research advances, TPX2 antibodies remain vital for unraveling mechanisms of cell division and developing targeted oncology treatments.
×
